<bill session="109" type="hc" number="311" updated="2013-07-19T20:04:50-04:00">
  <state datetime="2005-12-07">REFERRED</state>
  <status>
    <introduced datetime="2005-12-07"/>
  </status>
  <introduced datetime="2005-12-07"/>
  <titles>
    <title as="introduced" type="official">Urging Japan to honor its commitments under the 1986 Market-Oriented Sector-Selective (MOSS) Agreement on Medical Equipment and Pharmaceuticals, and for other purposes.</title>
  </titles>
  <sponsor id="400332"/>
  <cosponsors>
    <cosponsor id="400124" joined="2005-12-07"/>
    <cosponsor id="400291" joined="2005-12-13"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2005-12-07">
      <text>Referred to the House Committee on Ways and Means.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSWM" name="House Ways and Means" activity="Referral, In Committee"/>
  </committees>
  <relatedbills>
    <bill relation="unknown" session="109" type="sc" number="67"/>
  </relatedbills>
  <subjects>
    <term name="International affairs"/>
    <term name="Access to health care"/>
    <term name="Administrative procedure"/>
    <term name="Commerce"/>
    <term name="Drug approvals"/>
    <term name="Drugs"/>
    <term name="East Asia"/>
    <term name="Foreign trade and international finance"/>
    <term name="Health"/>
    <term name="International competitiveness"/>
    <term name="Japan"/>
    <term name="Law"/>
    <term name="Medical economics"/>
    <term name="Medical innovations"/>
    <term name="Medical supplies"/>
    <term name="Medical technology"/>
    <term name="Nontariff trade barriers"/>
    <term name="Prescription pricing"/>
    <term name="Science, technology, communications"/>
    <term name="Technological innovations"/>
    <term name="Trade agreements"/>
  </subjects>
  <amendments/>
  <summary>12/7/2005--Introduced.
Urges Japan to honor its commitments under the Market-Oriented Sector-Selective (MOSS) Agreement on Medical Equipment and Pharmaceuticals by: (1) reducing regulatory barriers to the approval and adoption of new medical technologies; (2) meeting or exceeding agency performance goals for premarket approvals and adopting an appropriate, risk-based postmarket system consistent with globally accepted practices; (3) promoting pricing policies that encourage innovation and eliminating reimbursement policies based on inappropriate comparisons to markets outside Japan; (4) implementing fair and open processes and rules that do not disproportionately harm U.S. medical technology products; and (5) providing opportunities for consultation with trading partners.</summary>
</bill>
